Gador wins Chile clearance for Gilead-licensed Biktarvy

Chile’s Institute of Public Health (ISP) last week published the approval it granted to Argentina-based laboratory Gador’s Gilead-licensed anti-HIV drug Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide), according to GBI analysis. The orally-administered combination therapy is indicated for the treatment of HIV-1 infection in adults with no current or previous viral resistance to integrase inhibitors, emtricitabine, or tenofovir.

Biktarvy contains three small-molecule inhibitors (SMIs) that hinder the viral replication cycle. Integrase strand transfer inhibitor (INSTI) bictegravir blocks the critical step of transferring viral genetic material into the host’s DNA. Meanwhile, antiretrovirals emtricitabine and tenofovir inhibit the activity of HIV-1 reverse transcriptase (RT) by competing with its natural substrates, and by signalling chain termination when incorporated into nascent viral DNA.

GBI analysis reveals that approval in Chile is Biktarvy's third market approval in Latin America, following registration earlier this year in Mexico, as well as in Argentina, where it is also licensed to Gador, as GBI reported.


Related news
US-based Gilead Sciences Inc., announced market approval from the National Medical Products Administration (NMPA) for its bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF; trade name: Biktarvy), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.
Chile’s Ministry of Health (MoH) last week initiated the free distribution of Gilead’s HIV pre-exposure prophylaxis (PrEP) drug Truvada (emtricitabine + tenofovir).
According to data from Mexico’s National Center for the Prevention and Control of HIV and AIDS (CENSIDA), the public health system has changed its efavirenz-based first-line HIV/AIDS treatment for Gilead’s Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide).
GBI analysis reveals that Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has granted registration approval to Gilead’s Genvoya (elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide; EVG/c/FTC/TAF), a single-tablet antiretroviral regimen for the treatment of HIV-1 infection.
US major Gilead Sciences Inc., (Nasdaq.GILD) is setting up an operational center in Chengdu, after signing a cooperation agreement with the Chengdu Hi-tech Zone, a state-backed industry park.
Recent news
Taiwan-based firm TaiGen Biophamaceuticals Holdings Ltd picked up a milestone payment of USD 5 million from Yichang HEC Changjiang Pharmaceutical Co., Ltd, its co-development partner for the hepatitis C virus (HCV) therapy furaprevir in China.
Innovative Chinese biotech Nanjing Frontier Biotech announced that it plans to raise RMB 2.01 billion (USD 286 million) through an initial public offering (IPO) to the Science and Technology Innovation Board (STAR) hosted by the Shanghai Stock Exchange (SSE).
  • 1566271018353
  • China
Pharmaceutical major Amgen has transferred Dominican Republic-born Elvin Penn from its Mexico subsidiary to head its operations in Brazil.
A team of researchers in Argentina has identified tumor-supportive mechanisms derived from interactions between fibroblasts and anaplastic thyroid cancer cells, the most aggressive type of thyroid cancer with a worse prognosis for patients.
  • 1566206139500
  • Argentina
  • R&D
Shanghai-based Haihe Biopharma announced its latest in-licensing and partnership deal with the Shanghai Institute of Materia Medica (SIMM, affiliated to the Chinese Academy of Sciences) and Jinan University.
  • 1566205390010
  • China
  • Drug
GBI analysis reveals that Chile’s Institute of Public Health (ISP) last week published its approval of Austria-based Ever Pharma Jena’s Everpressin (terlipressin), a first-mover generic version of Switzerland-based Ferring’s hormone analogue Glypressin.
The China Securities Regulatory Commission (CSRC) released details of the administrative punishments it is levelling against senior executives at Kangmei Pharmaceutical Co., Ltd, in response to the discovery that the firm had fraudulently overstated its cash holdings from 2016 to August 2018 by over USD 12 billion.
Analytics Snapshot

Analytics Snapshot